人β防御素-1、-2、-3表达水平与口腔鳞状细胞癌临床病理特征间的关系  

Relationship between hBD-1,hBD-2 and hBD-3 Expression and Clinicopathologic Characteristics of Oral Squamous Cell Carcinoma

作　　者：周倩[1,2,3] 王文梅[1,2,3] 王翔[1,2,3] 叶沛[1,2,3] 钱雅洁[1,2,3] 黎景景 

机构地区：[1]南京大学口腔医学院 [2]南京大学医学院附属口腔医院 [3]南京市口腔医院牙体牙髓科,江苏南京210008

出　　处：《口腔医学研究》2014年第10期949-952,957,共5页Journal of Oral Science Research

基　　金：国家自然科学基金项目(编号:81070839);江苏省六大人才高峰项目(编号:2010-WS-004);南京市医学科技发展重点项目(编号:ZKX10030)

摘　　要：目的:研究人β防御素(humanβ-defensin,hBD)-1、hBD-2、hBD-3的表达水平与口腔鳞癌临床病理特征间的关系。方法:采用免疫组织化学染色法检测了hBD-1、hBD-2和hBD-3在60例OSCC中的表达,软件测定其平均光密度值(mean optical density,MA),并分析其与临床病理特征的相关性。结果:中分化和低分化组中hBD-2和hBD-3的MA值显著低于高分化组(P<0.01)。伴有淋巴结转移组hBD-2的MOD值显著高于无淋巴结转移组(P<0.01)。肿瘤直径≥2cm组hBD-3的MOD值显著低于肿瘤直径<2cm组(P<0.01)。结论:hBD-2的蛋白表达与OSCC的分化和淋巴结转移相关,hBD-3的蛋白表达与OSCC分化和大小相关。Objective：To investigate the relationship between expression of human beta defensin（hBD）-1,hBD-2,hBD-3and clinicopathologic characteristics of oral squamous cell cancer（OSCC）.Methods：In this study,immunohistochemistry staining was used to detect the hBD-1,hBD-2and hBD-3expression in 60 cases of oral squamous cell carcinoma.The mean optical density（MOD）of immunohistochemical staining was measured.The relationship between the immunohistochemical results and clinicopathological characteristics of OSCC was evaluated.Results：The expression of hBD-2and hBD-3in OSCC patients with moderate differentiation and patients with poor differentiation were significantly lower than patients with well differentiation（P〈0.01）.The MOD of hBD2 immunostaining in OSCC patients with lymph node metastasis was significant higher than that in patients without lymph node metastasis（P〈0.01）.The MOD of hBD3 immunostaining in patients with larger tumor size（≥2cm）was significantly lower than that in patients with smaller tumor size（〈2cm）（P〈0.01）.Conclusion：The expression of hBD-2could be associated with differentiation and lymph node metastasis of OSCC.The expression of hBD-2could be associated with differentiation and tumor size of OSCC.

关 键 词：口腔鳞状细胞癌 β-防御素1 Β-防御素2 β-防御素3 临床病理 

分 类 号：R739.8[医药卫生—肿瘤]